{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:34:19Z","timestamp":1740155659817,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T00:00:00Z","timestamp":1418688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1038\/nrneph.2014.241","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T07:15:15Z","timestamp":1418714115000},"page":"129-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HALTing PKD progression\u2014revival of blood pressure control"],"prefix":"10.1038","volume":"11","author":[{"given":"Thomas","family":"Benzing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,16]]},"reference":[{"key":"BFnrneph2014241_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nrneph.2014.173","volume":"10","author":"CE Kurschat","year":"2014","unstructured":"Kurschat, C. E.  et al. An approach to cystic kidney diseases: the clinician's view. Nat. Rev. Nephrol. 10, 687\u2013699 (2014).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2014241_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ndt\/gfu017","volume":"29","author":"EM Spithoven","year":"2014","unstructured":"Spithoven, E. M.  et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry. Nephrol. Dial. Transplant. 29 (Suppl. 4), 15\u201325 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2014241_CR3","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1681\/ASN.2013111184","volume":"25","author":"RW Schrier","year":"2014","unstructured":"Schrier, R. W.  et al. Predictors of autosomal dominant polycystic kidney disease progression. J. Am. Soc. Nephrol. 25, 2399\u20132418 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"doi-asserted-by":"publisher","unstructured":"Schrier, R. W.  et al. Blood Pressure in early autosomal dominant polycystic kidney disease. N. Engl. J. Med. \n                    http:\/\/dx.doi.org\/10.1056\/NEJMoa1402685\n                    \n                  .","key":"BFnrneph2014241_CR4","DOI":"10.1056\/NEJMoa1402685"},{"doi-asserted-by":"publisher","unstructured":"Torres, V. E.  et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N. Engl. J. Med. \n                    http:\/\/dx.doi.org\/10.1056\/NEJMoa1402686\n                    \n                  .","key":"BFnrneph2014241_CR5","DOI":"10.1056\/NEJMoa1402686"},{"key":"BFnrneph2014241_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2215\/CJN.04310709","volume":"5","author":"AB Chapman","year":"2010","unstructured":"Chapman, A. B.  et al. The HALT polycystic kidney disease trials: design and implementation. Clin. J. Am. Soc. Nephrol. 5, 102\u2013109 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2014241_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nrneph.2014.132","volume":"10","author":"E Cornec-Le Gall","year":"2014","unstructured":"Cornec-Le Gall, E. & Le Meur, Y. Polycystic kidney disease: Kidney volume\u2014a crystal ball for ADPKD prognosis? Nat. Rev. Nephrol. 10, 485\u2013486 (2014).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2014241_CR8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz, G.  et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830\u2013840 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2014241_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra, A. L.  et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820\u2013829 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2014241_CR10","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E.  et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407\u20132418 (2012).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.241","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:44:32Z","timestamp":1684471472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2014.241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,16]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["BFnrneph2014241"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2014.241","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"type":"print","value":"1759-5061"},{"type":"electronic","value":"1759-507X"}],"subject":[],"published":{"date-parts":[[2014,12,16]]},"assertion":[{"value":"16 December 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.B. receives speaker honoraria from Hexal, Novartis and Otsuka.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}